Cargando…

Lomitapide does not alter PCSK9 and Lp(a) levels in homozygous familial hypercholesterolemia patients: Analysis on cytokines and lipid profile

Lomitapide, a drug for the treatment of homozygous familial hypercholesterolemia patients, reduced total and LDL cholesterol but no significant changes were observed on PCSK9 and Lp(a) plasma levels. Some changes of inflammatory mediators were also observed, including hsCRP, which may suggest an ant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lupo, Maria Giovanna, Arcidiacono, Diletta, Zaramella, Alice, Fimiani, Fabio, Calabrò, Paolo, Cefalù, Angelo Baldassare, Averna, Maurizio, D'Erasmo, Laura, Arca, Marcello, De Martin, Sara, Zambon, Alberto, Ferri, Nicola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9833247/ https://www.ncbi.nlm.nih.gov/pubmed/36644506 http://dx.doi.org/10.1016/j.athplu.2021.05.001

Ejemplares similares

Long‐term hepatic safety of lomitapide in homozygous familial hypercholesterolaemia
por: Larrey, Dominique, et al.
Publicado: (2022)

Long-term efficacy of lipoprotein apheresis and lomitapide in the treatment of homozygous familial hypercholesterolemia (HoFH): a cross-national retrospective survey
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Efficacy of Long-Term Treatment of Autosomal Recessive Hypercholesterolemia With Lomitapide: A Subanalysis of the Pan-European Lomitapide Study
por: D’Erasmo, Laura, et al.
Publicado: (2022)

Efficacy and Safety of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2017)

Rare Treatments for Rare Dyslipidemias: New Perspectives in the Treatment of Homozygous Familial Hypercholesterolemia (HoFH) and Familial Chylomicronemia Syndrome (FCS)
por: D’Erasmo, Laura, et al.
Publicado: (2021)

Lomitapide–a Microsomal Triglyceride Transfer Protein Inhibitor for Homozygous Familial Hypercholesterolemia
por: Stefanutti, Claudia
Publicado: (2020)

Gradual dose Titration of Lomitapide may Prevent Therapeutic Delays in Patients with Homozygous Familial Hypercholesterolemia
por: Harada-Shiba, Mariko, et al.
Publicado: (2023)

Homozygous Familial Hypercholesterolemia (HoFH) in Saudi Arabia and Two Cases of Lomitapide Use in a Real-World Setting
por: Mahzari, Moeber, et al.
Publicado: (2021)

Dietary Intake during 56 Weeks of a Low-Fat Diet for Lomitapide Treatment in Japanese Patients with Homozygous Familial Hypercholesterolemia
por: Kameyama, Noriko, et al.
Publicado: (2019)

A First-in-Class Drug, Lomitapide, Tailored to Patients with Homozygous Familial Hypercholesterolemia is Just about Meeting with Good News to Them
por: Yoshida, Hiroshi
Publicado: (2017)

Target achievement and cardiovascular event rates with Lomitapide in homozygous Familial Hypercholesterolaemia
por: Blom, Dirk J., et al.
Publicado: (2018)

Lomitapide treatment in a female with homozygous familial hypercholesterolaemia: a case report
por: Littmann, Karin, et al.
Publicado: (2020)

Real-World Outcomes with Lomitapide Use in Paediatric Patients with Homozygous Familial Hypercholesterolaemia
por: Ben-Omran, Tawfeg, et al.
Publicado: (2019)

Safety and Efficacy of Lomitapide in Japanese Patients with Homozygous Familial Hypercholesterolemia (HoFH): Results from the AEGR-733-301 Long-Term Extension Study
por: Nohara, Atsushi, et al.
Publicado: (2019)

Effects of PCSK9 inhibitors on HDL cholesterol efflux and serum cholesterol loading capacity in familial hypercholesterolemia subjects: a multi-lipid-center real-world evaluation
por: Palumbo, Marcella, et al.
Publicado: (2022)

Homozygous familial hypercholesterolemia
por: Parihar, Ravi Kumar, et al.
Publicado: (2012)

Homozygous Familial Hypercholesterolemia
por: Nohara, Atsushi, et al.
Publicado: (2021)

PCSK9 Antibodies for the Treatment of Hypercholesterolemia
por: Gouni-Berthold, Ioanna, et al.
Publicado: (2014)

Elevated PCSK9 Levels in Untreated Patients With Heterozygous or Homozygous Familial Hypercholesterolemia and the Response to High‐Dose Statin Therapy
por: Raal, Frederick, et al.
Publicado: (2013)

Lipoprotein(a) Genotype Influences the Clinical Diagnosis of Familial Hypercholesterolemia
por: Olmastroni, Elena, et al.
Publicado: (2023)

Xanthoma tuberosum in homozygous familial hypercholesterolemia
por: Moorthy, Nagaraja, et al.
Publicado: (2014)

Liver Transplantation for Homozygous Familial Hypercholesterolemia
por: Ishigaki, Yasushi, et al.
Publicado: (2019)

Treatment of Homozygous Familial Hypercholesterolemia With Evinacumab
por: Jeraj, Natasha, et al.
Publicado: (2021)

Advancements in the Treatment of Homozygous Familial Hypercholesterolemia
por: Bajaj, Archna, et al.
Publicado: (2022)

Antiplatelet Effects of PCSK9 Inhibitors in Primary Hypercholesterolemia
por: Pęczek, Piotr, et al.
Publicado: (2021)

Role of PCSK9 Inhibitors in Patients with Familial Hypercholesterolemia
por: Tomlinson, Brian, et al.
Publicado: (2021)

A PCSK9 inhibitor induces a transient decrease in the neutrophil-lymphocyte ratio and monocyte-lymphocyte ratio in homozygous familial hypercholesterolemia patients
por: Li, Fangyuan, et al.
Publicado: (2022)

Effectiveness of clinical scores in predicting coronary artery disease in familial hypercholesterolemia: a coronary computed tomography angiography study
por: Catapano, Federica, et al.
Publicado: (2023)

Metabolic effects of PCSK9 inhibition with Evolocumab in subjects with elevated Lp(a)
por: Zhang, Xiang, et al.
Publicado: (2020)

Twelve Variants Polygenic Score for Low‐Density Lipoprotein Cholesterol Distribution in a Large Cohort of Patients With Clinically Diagnosed Familial Hypercholesterolemia With or Without Causative Mutations
por: Olmastroni, Elena, et al.
Publicado: (2022)

Role of Nutraceuticals in Hypolipidemic Therapy
por: Barbagallo, Carlo M., et al.
Publicado: (2015)

Genetic screening for homozygous and heterozygous familial hypercholesterolemia
por: Izar, Maria C, et al.
Publicado: (2010)

Challenges in the Diagnosis and Treatment of Homozygous Familial Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2015)

Homozygous familial hypercholesterolemia with an update on cholesterol management
por: Velvet, Anju J J, et al.
Publicado: (2020)

New algorithms for treating homozygous familial hypercholesterolemia
por: Tromp, Tycho R., et al.
Publicado: (2022)

Current Treatment Options in Homozygous Familial Hypercholesterolemia
por: Kayikcioglu, Meral, et al.
Publicado: (2022)

Lipid-Lowering Therapy in Patients with Coronary Heart Disease and Prior Stroke: Mission Impossible?
por: Temporelli, Pier Luigi, et al.
Publicado: (2021)

Naturally Occurring PCSK9 Inhibitors
por: Adorni, Maria Pia, et al.
Publicado: (2020)

A Case Series Assessing the Effects of Lomitapide on Carotid Intima-Media Thickness in Adult Patients with Homozygous Familial Hypercholesterolaemia in a Real-World Setting
por: Blom, Dirk J., et al.
Publicado: (2022)

PCSK9 Inhibition With Monoclonal Antibodies: Modern Management of Hypercholesterolemia
por: Ito, Matthew K., et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_rm3soamnmldrurv8bhc87iikap